
Marengo Therapeutics to Present STARt-002 Combination Trial Results
Interim findings from the STARt-002 clinical study have been selected for an oral presentation at the upcoming Society for Immunotherapy of Cancer annual meeting. The trial marks the first time researchers have paired a Vβ6-selective T-cell agonist, invikafusp alfa, with the antibody-drug conjugate TRODELVY to treat metastatic breast cancer.



























